Osphena vs Duavee: Cost, Access, and Which One Fits Your Menopause

What Are These Two Drugs, Exactly?

Osphena and Duavee are both oral menopause medications, but they work through different mechanisms and were designed to solve different problems. Knowing the distinction upfront saves you from chasing the wrong prescription.

Osphena contains ospemifene, a selective estrogen receptor modulator (SERM). It acts like estrogen in vaginal tissue specifically, which is why it improves the vaginal lining and reduces pain with sex. In breast tissue, it behaves more like an estrogen blocker. The FDA approved it in 2013 for moderate-to-severe dyspareunia due to menopause and later added vaginal dryness as an indication.

Duavee is a tissue-selective estrogen complex (TSEC). It pairs conjugated estrogens (CE) with bazedoxifene, another SERM. The bazedoxifene component blocks estrogen's effect on the uterine lining, so women with a uterus do not need to add a separate progestin. The SMART (Selective estrogens, Menopause, And Response to Therapy) trials validated this combination for hot-flash reduction and bone preservation.

Neither drug is interchangeable with the other in a direct clinical sense. Think of Osphena as a vaginal-tissue specialist and Duavee as a whole-body estrogen replacement with a built-in uterine protector.

How Each Drug Was Studied: The Key Trials

The Ospemifene VVA Randomized Controlled Trial

The key phase 3 randomized controlled trial that led to Osphena's approval enrolled postmenopausal women with moderate-to-severe symptoms of vulvovaginal atrophy (VVA). At 12 weeks, ospemifene 60 mg daily significantly improved the vaginal maturation index, reduced vaginal pH, and reduced the severity of dyspareunia compared with placebo. The vaginal maturation index shifted meaningfully toward a healthier, more estrogenized pattern. Hot-flash frequency was not a primary endpoint, and Osphena is not indicated for vasomotor symptoms.

The SMART Trials for Duavee

The SMART trial program, a series of phase 3 studies, tested CE 0.45 mg plus bazedoxifene 20 mg across multiple endpoints. SMART-1 demonstrated significant reductions in mean daily hot-flash frequency and severity, along with preservation of bone mineral density at the lumbar spine and hip compared with placebo over 12 months. Critically, endometrial safety data showed no increase in endometrial hyperplasia, which means bazedoxifene fulfilled its protective role without requiring a progestin add-on. Vaginal symptoms improved modestly, but they were not the primary target.

What No Head-to-Head Trial Exists to Tell You

No published randomized trial has directly compared Osphena with Duavee head-to-head. Any comparison of their efficacy relies on indirect, cross-trial data from different populations, different endpoint definitions, and different follow-up periods. This evidence gap matters. Women have been historically under-represented in menopause pharmacology trials, and direct comparative effectiveness studies in postmenopausal women with overlapping symptom clusters are essentially absent from the published literature.

To make a practical decision, you and your clinician compare trial-population profiles, not drug-versus-drug efficacy numbers that do not exist.

Symptom Match: Which Drug Is Designed for Your Chief Complaint?

This is the clearest decision filter available.

| Your main symptom | Better-matched drug | Why | |---|---|---| | Painful sex (dyspareunia) | Osphena | Directly studied endpoint in VVA RCT | | Vaginal dryness without interest in vaginal products | Osphena | FDA-approved indication | | Frequent, moderate-to-severe hot flashes | Duavee | Primary SMART trial endpoint | | Osteoporosis prevention (no progestin preferred) | Duavee | Bone mineral density data from SMART | | Both hot flashes and mild vaginal dryness | Discuss Duavee first | SMART showed some vaginal benefit | | Both dyspareunia and hot flashes | No single pill covers both well; discuss adding low-dose vaginal estrogen to either | Off-label layering; evidence limited |

If your only bothersome symptom is painful intercourse or dryness and you have a uterus, Osphena is typically the first oral non-vaginal option discussed. If hot flashes are keeping you awake and affecting your quality of life, Duavee fits the clinical profile better.

Female-Specific Physiology: How Hormonal Status Shapes These Drugs

Both drugs are indicated only in postmenopausal women. Neither should be started during perimenopause, when estrogen levels are erratic rather than consistently low. Using a SERM like ospemifene while estrogen is still fluctuating can produce unpredictable receptor-level effects. Duavee's conjugated estrogens can also cause unscheduled uterine bleeding if started before menopause is fully established (defined as 12 consecutive months without a period, or FSH above 40 IU/L with symptoms in a woman who has had her uterus).

PCOS and Metabolic History

Women with a history of PCOS who reach menopause may carry residual metabolic risk, including dyslipidemia and insulin resistance. Ospemifene has a SERM-class label warning about thromboembolic events. Conjugated estrogens also carry this risk. If you have prior venous thromboembolism (VTE) or known thrombophilia, both drugs require a careful benefit-risk conversation. The FDA label for Osphena carries a boxed warning for cardiovascular disorders and thromboembolic events, mirroring the class effect of systemic SERMs.

Women with a History of Breast Cancer or High Breast Density

Ospemifene has estrogen-agonist effects in bone and vaginal tissue but antagonist (or neutral) effects in breast tissue in preclinical models. However, it is not approved for use in women with known or suspected breast cancer. The Menopause Society's 2023 position statement on hormone therapy states that non-hormonal and non-systemic therapies are preferred for breast cancer survivors with GSM. Duavee contains systemic conjugated estrogens and is similarly contraindicated in women with current or past estrogen-receptor-positive breast cancer.

Endometrial Protection: Why Duavee's Design Matters

If you have a uterus and take systemic estrogen without adequate progestogenic opposition, you increase your risk of endometrial hyperplasia and cancer. Standard hormone therapy pairs estrogen with a progestin. Duavee replaces the progestin with bazedoxifene, which blocks estrogen's proliferative effect on the endometrium. The SMART trial endometrial safety data at 12 months showed no cases of hyperplasia in the CE 0.45 mg/bazedoxifene 20 mg group, confirming that bazedoxifene provides adequate uterine protection without a progestin.

Osphena, as a SERM, has mixed effects on the endometrium. Clinical trial data showed a small but statistically significant increase in endometrial thickness with ospemifene 60 mg at 12 weeks, though no cases of hyperplasia or cancer were reported. Any unexplained uterine bleeding on Osphena warrants evaluation.

Pregnancy, Lactation, and Contraception: Required Reading

Both drugs are contraindicated in pregnancy.

This section is not optional reading for any woman who has even a small chance of pregnancy, including perimenopausal women who have not yet confirmed 12 consecutive months without a period.

Osphena in Pregnancy

Ospemifene is pregnancy category X. Animal reproduction studies showed fetal harm at doses producing exposures similar to those in humans. The FDA label states that ospemifene may cause fetal harm and must not be used during pregnancy. There are no adequate human data on fetal outcomes with ospemifene exposure. If you are perimenopausal and still ovulating, use a reliable non-hormonal contraceptive method while taking Osphena. Barrier methods (copper IUD, condoms) are the most straightforward options since combined hormonal contraceptives interact with estrogen-pathway drugs.

Duavee in Pregnancy

Conjugated estrogens plus bazedoxifene is also contraindicated in pregnancy. Exogenous estrogens can cause fetal harm; bazedoxifene, as a SERM, poses additional risk given the class effects of SERMs on fetal development. There are no human pregnancy data for this specific combination. Do not use Duavee if there is any possibility of pregnancy.

Lactation

Neither drug should be taken while breastfeeding. Ospemifene's transfer into human breast milk has not been studied. Estrogens are known to suppress lactation and pass into breast milk in detectable amounts. Given that both drugs are indicated only for postmenopausal women, breastfeeding is an unlikely scenario, but postpartum women who have experienced premature ovarian insufficiency (POI) or surgical menopause should be aware that neither drug is appropriate during lactation.

A Note on Postpartum and Premature Menopause

Women under age 40 with POI who reach menopause early represent a distinct group. Neither Osphena nor Duavee has been studied in POI populations specifically. Evidence for GSM management in younger women with POI is largely extrapolated from trials conducted in women aged 50-65. This is an evidence gap that your clinician should acknowledge when selecting therapy.

Cost and Insurance Access: Real Numbers

Cost is often the deciding factor after the symptom match is clear.

Cash Prices (Without Insurance)

As of early 2025, the cash price for a 30-day supply of Osphena 60 mg runs approximately $350 to $420 at major US pharmacies. Duavee typically runs $290 to $380 for 30 days. Both are branded, with no generic available in the United States as of this writing. Ospemifene does not yet have an approved generic in the US market, though the patent field has been contested.

Insurance Coverage Patterns

Commercial insurance coverage for both drugs is inconsistent. Many plans classify them as Tier 3 or Tier 4 specialty drugs, requiring prior authorization. Prior authorization for Osphena often requires documented failure or contraindication to vaginal estrogen. Duavee's prior authorization criteria typically require documentation of moderate-to-severe hot flashes.

Medicare Part D coverage varies by plan. Neither drug consistently lands on preferred formulary tiers in Medicare plans, which means many postmenopausal women on fixed incomes face high cost sharing. The Centers for Medicare and Medicaid Services notes that formulary decisions for women's menopause medications have been inconsistent across plan types, and advocacy groups have raised concerns about access barriers for non-contraceptive hormonal drugs.

Manufacturer Savings Programs

Osphena: Shionogi, the manufacturer, offers a co-pay savings card that can reduce out-of-pocket costs to as low as $30 per month for eligible commercially insured patients. This program does not apply to Medicare or Medicaid recipients.

Duavee: Pfizer has offered savings programs for Duavee that similarly target commercially insured patients. Eligibility rules change, so verify current terms directly at the manufacturer's patient assistance page.

GoodRx and pharmacy discount programs sometimes bring the cash price of Duavee below $250 at certain pharmacies. Osphena responds less predictably to GoodRx discounts given manufacturer pricing controls, but comparison-shopping across pharmacies can save $50 to $80 per fill.

Compounding as a Cost Alternative

Some compounding pharmacies prepare ospemifene in custom formulations. Compounded preparations are not FDA-approved, lack the bioavailability and stability data of the commercial product, and are not covered by insurance. The FDA has issued guidance cautioning patients about compounded hormone preparations due to concerns about potency variability and sterility. If cost is the barrier, the manufacturer savings program and telehealth-negotiated pharmacy pricing are generally more reliable routes.

Who This Is Right For, and Who It Is Not

Osphena Is a Good Fit If You:

• Are postmenopausal and your primary complaint is painful sex or significant vaginal dryness
• Prefer an oral pill over vaginal creams, rings, or suppositories
• Have no history of VTE or active thromboembolic disease
• Have no current or prior estrogen-receptor-positive breast cancer
• Are not pregnant and, if perimenopausal, are using reliable contraception

Osphena Is Not a Good Fit If You:

• Have moderate-to-severe hot flashes as your main symptom
• Have a personal or strong family history of VTE without hematology clearance
• Are currently pregnant or breastfeeding
• Have undiagnosed vaginal bleeding

Duavee Is a Good Fit If You:

• Are postmenopausal with moderate-to-severe hot flashes disrupting your sleep or daily function
• Want systemic hormone therapy but prefer to avoid adding a separate progestin (and have a uterus)
• Have concerns about bone density and want a single drug that addresses both vasomotor symptoms and skeletal protection
• Have no history of estrogen-sensitive breast cancer or active thromboembolic disease

Duavee Is Not a Good Fit If You:

• Have had a hysterectomy (in which case, standard estrogen alone is simpler and cheaper)
• Are primarily looking for relief from GSM/dyspareunia with no significant hot flashes
• Are pregnant, planning pregnancy, or breastfeeding
• Have a known or suspected estrogen-dependent tumor

Can You Switch Between Them?

Switching is clinically possible, but not always straightforward. If you start on Osphena for GSM and later develop significant hot flashes, your clinician may transition you to Duavee. The wash-out period between drugs is not formally defined in guidelines, but most menopause specialists allow a brief gap of a few days to a week before starting the new agent to avoid additive SERM effects. The Menopause Society recommends shared decision-making when adjusting menopause hormone regimens, with reassessment of symptom burden and risk profile at each transition.

Going the other direction, from Duavee to Osphena, is less common. If your hot flashes resolve but dyspareunia remains, low-dose vaginal estrogen added to continued Duavee is an option many clinicians prefer over switching entirely, since vaginal-specific dosing minimizes systemic exposure.

The key clinical rule: do not take both drugs simultaneously without specialist guidance. Combining a SERM (ospemifene) with another SERM-containing product (bazedoxifene in Duavee) creates unpredictable receptor competition. There is no published human safety data for this combination.

Side-Effect Profiles: What to Expect

Osphena Side Effects

The most commonly reported side effects in the key trial were hot flashes, which occurred in approximately 7.5% of ospemifene-treated women versus 2.6% in the placebo group. This is relevant: Osphena can worsen or trigger vasomotor symptoms in some women, which makes it a particularly poor choice if you already have significant hot flashes.

Other reported side effects include vaginal discharge (a sign of the estrogenic effect on vaginal tissue, not necessarily a problem), muscle spasms, and hyperhidrosis. The boxed warning covers VTE and stroke risk consistent with the SERM class.

Duavee Side Effects

Common side effects reported in the SMART trials included muscle spasms, nausea, diarrhea, dyspepsia, and upper abdominal pain. Hot-flash frequency was the primary endpoint being treated, not caused, though some women report a temporary worsening in the first two weeks of therapy as estrogen levels stabilize. The boxed warning for Duavee is consistent with other systemic estrogen-containing products: VTE, stroke, and the theoretical risk of endometrial cancer if the bazedoxifene component is somehow insufficient (though SMART data did not show this).

Monitoring and Follow-Up by Life Stage

Early postmenopause (within 10 years of final menstrual period or under age 60): Both drugs are generally considered appropriate in this window. The "timing hypothesis" suggests systemic estrogen exposure is less risky in the early postmenopausal years; this logic applies most directly to Duavee's estrogen component.

Late postmenopause (beyond 10 years or over age 65): Initiating systemic estrogen therapy in this window carries higher cardiovascular and VTE risk. Osphena, as a non-systemic-estrogen SERM, may carry less cardiovascular risk than Duavee in this group, though direct data are limited. Vaginal estrogen at low doses remains the safest GSM intervention for older postmenopausal women.

Women with surgical menopause: Younger women who underwent bilateral oophorectomy have more severe and abrupt menopause than natural menopause. Both drugs have limited data in this population specifically, and doses were not calibrated for the more severe estrogen deficiency that follows surgical menopause.

Follow-up at 3 months after starting either drug is standard practice to assess symptom response, tolerability, and any unexpected bleeding. Annual review of the continued need for therapy is recommended by The Menopause Society's 2022 hormone therapy position statement.

The Honest Evidence Summary

Clinical trial data for both drugs comes from 12-month trials in postmenopausal women aged roughly 40-80, but the majority of participants were in their early 50s and 60s, were white, and had no major comorbidities. Extrapolation to women with complex medical histories, racial and ethnic diversity, and advanced age requires caution. The ospemifene VVA trial enrolled women specifically for GSM; the SMART trials enrolled women for vasomotor symptoms. Comparing across these two populations is methodologically imprecise.

As the American College of Obstetricians and Gynecologists states in its menopause guidance, no single hormone therapy regimen is appropriate for all women, and individualization based on symptoms, risks, and values is the standard of care.

The practical upshot: ask your clinician to name the specific symptom or risk that each drug is being prescribed to address. If the answer is clear, the drug choice usually follows.